IRLAB: Invitation to the interim report for Q3 2026 presentation and webcast
Gothenburg, Sweden, November 6, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January – September 2026. The interim report will be published on Friday, November 13, 2026, at 07:00 CEST.
Gothenburg, Sweden, November 6, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January – September 2026. The interim report will be published on Friday, November 13, 2026, at 07:00 CEST.
The presentation will be held on November 13, 2026, at 11:30 CET via digital webcast. Kristina Torfgård, CEO, Nicholas Waters, EVP and Head of R&D, and Gustaf Albèrt, CFO, will comment the interim report. The presentation will be held in Swedish and will be followed by a Q&A session.
Follow the webcast online: https://youtube.com/live/BVyS3xkV3vU?feature=share
The interim report and the presentation will be available on www.irlab.se, and the recorded version of the presentation will be available shortly afterward.